Amicus Therapeutics Inc Cash Flow Conversion Efficiency
Amicus Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Amicus Therapeutics Inc (FOLD) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($16.25 Million) by net assets ($274.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Amicus Therapeutics Inc (2005–2025)
Cash flow conversion efficiency of Amicus Therapeutics Inc from 2005 to 2025. This chart illustrates how Amicus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Amicus Therapeutics Inc stock quote for real-time trading data and today's change.
Amicus Therapeutics Inc Cash Flow Conversion Ratio Explained
Amicus Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Amicus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amicus Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Amicus Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou TA&A Ultra Clean Technology Co Ltd
SHE:300390
|
-0.037x |
|
Montage Gold Corp.
TO:MAU
|
-0.017x |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
0.011x |
|
China Vanke Co Ltd Class A
SHE:000002
|
-0.006x |
|
MakeMyTrip Limited
NASDAQ:MMYT
|
-0.163x |
|
RioCan Real Estate Investment Trust
TO:REI-UN
|
0.024x |
|
Moelis & Co
NYSE:MC
|
0.361x |
|
Thai Airways International Public Company Limited
BK:THAI
|
0.005x |
Annual Cash Flow Conversion Efficiency for Amicus Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Amicus Therapeutics Inc from 2005 to 2025. Review Amicus Therapeutics Inc (FOLD) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $274.24 Million | $33.15 Million | 0.121x | +169.20% |
| 2024-12-31 | $194.04 Million | $-33.89 Million | -0.175x | +59.51% |
| 2023-12-31 | $160.17 Million | $-69.09 Million | -0.431x | +68.14% |
| 2022-12-31 | $123.05 Million | $-166.57 Million | -1.354x | -105.49% |
| 2021-12-31 | $307.37 Million | $-202.49 Million | -0.659x | +19.13% |
| 2020-12-31 | $286.38 Million | $-233.29 Million | -0.815x | -54.98% |
| 2019-12-31 | $476.43 Million | $-250.42 Million | -0.526x | +39.91% |
| 2018-12-31 | $342.91 Million | $-299.95 Million | -0.875x | -43.23% |
| 2017-12-31 | $352.85 Million | $-215.49 Million | -0.611x | -46.11% |
| 2016-12-31 | $360.15 Million | $-150.53 Million | -0.418x | -45.18% |
| 2015-12-31 | $347.83 Million | $-100.14 Million | -0.288x | +31.92% |
| 2014-12-31 | $122.18 Million | $-51.67 Million | -0.423x | +57.75% |
| 2013-12-31 | $45.75 Million | $-45.79 Million | -1.001x | -105.33% |
| 2012-12-31 | $69.22 Million | $-33.74 Million | -0.487x | +70.81% |
| 2011-12-31 | $29.59 Million | $-49.42 Million | -1.670x | -675.56% |
| 2010-12-31 | $64.93 Million | $-13.98 Million | -0.215x | +64.33% |
| 2009-12-31 | $71.83 Million | $-43.37 Million | -0.604x | -16.36% |
| 2008-12-31 | $71.04 Million | $-36.86 Million | -0.519x | -452.81% |
| 2007-12-31 | $103.30 Million | $15.19 Million | 0.147x | -66.36% |
| 2006-12-31 | $-77.52 Million | $-33.89 Million | 0.437x | -13.57% |
| 2005-12-31 | $-35.83 Million | $-18.12 Million | 0.506x | -- |
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha … Read more